

Literatur

1. Herzbericht 2009; <http://www.aerzteblatt.de/nachrichten/43029>
2. Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management – what does it mean in practice? *Vasc Health Risk Manag* 2007; 3:587-603.
3. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol* 2009; 54:2129-2138.
4. Schwandt P, Parhofer K. *Handbuch der Fettstoffwechselstörungen*, 3. Auflage, 2007, Verlag Schattauer.
5. Daniels TF, Killinger KM, Michal JJ, Wright Jr RW, Jiang Z. Lipoproteins, cholesterol homeostasis and cardiac health. *Int J Sci* 2009; 5:474-488.
6. Biggerstaff KD, Wooten JS. Understanding lipoproteins as transporters of cholesterol and other lipids. *Adv Physiol Educ* 2004; 28:105-106.
7. Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. *J Atheroscler Thromb* 2009; 16:145-154.
8. National Cholesterol Education Programm (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *Circulation* 2002; 106:3143-3421.
9. Grundy SM, Cleeman JE, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program. *Circulation* 2004; 110:227-239.
10. Graham I, et al; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2007; 28:2375-2414.
11. Williams KJ. Molecular processes that handle – and mishandle – dietary lipids. *J Clin Invest* 2008; 118:3247-3259.
12. Mesmin B, Maxfield FR. Intracellular sterol dynamics. *Biochim Biophys Acta* 2009; 179:636-645.
13. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005; 366:1267-1278.
14. Gleissner CA, Leitinger N, Ley K. Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis. *Hypertension* 2007; 50:276-283.
15. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. *Q J Med* 2006; 99:1-14.
16. Virella G, Lopez-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. *Atherosclerosis* 2008; 200:239-246.
17. Steinberg D. The LDL-modification hypothesis of atherogenesis: an update. *J Lipid Res* 2009; 50:S376-S381.
18. Rye K-A, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. *J Lipid Res* 2009; 50:S195-S200.
19. Lewis GF, Rader DJ. New Insights into the regulation of HDL metabolism and reverse cholesterol transport. *Circ Res* 2005; 96:1221-1232.
20. Sharma RK, Singh VN, Reddy HK. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. *Vasc Health Risk Manag* 2009; 5:793-799.

21. Rapp RJ. Hypertriglyceridemia: a review beyond low-density lipoprotein. *Cardiol Rev* 2002; 10:163-172.
22. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA* 2007; 298:299-308.
23. Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. *Vasc Health Risk Manag* 2009; 5:89-95.
24. Iqbal J, Hussain MM. Intestinal lipid absorption. *Am J Physiol Endocrinol Metab* 2009; 296:E1183-E1194.
25. Berliner JA, Gharavi NM. Endothelial cell regulation by phospholipid oxidation products. *Free Radic Biol Med* 2008; 45:119-123.
26. Madjid M, Ali M, Willerson JT. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease. *Tex Heart Inst J* 2010; 37:25-39.
27. Berglund L, Ramakrishnan R. Lipoprotein(a) - An elusive cardiovascular risk factor. *Arterioscler Thromb Vasc Biol* 2004; 24:2219-2226.
28. The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009; 302:412-423.
29. Tsimikas S, Tsimikas LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipases A2 in atherosclerosis and cardiovascular disease. *Arterioscler Thromb Vasc Biol* 2007; 27:2094-2099.
30. Anuurad E, Enkhmaa B, Berglund L. Enigmatic role of lipoprotein(a) in cardiovascular disease. *Clin Trans Sci* 2010; 3:327-332.
31. Rye K-A, Barter BJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. *Arterioscler Thromb Vasc Biol* 2004; 24:421-428.
32. Jones MK, Cate A, Li L, Segrest JP. Dynamics of lecithin:cholesterolacyltransferase activation by apolipoprotein A-I. *Biochemistry* 2009; 48:11196-11210.
33. Nofer J-R, Remaley AT. Tangier disease: still more questions than answers. *Cell Mol Life Sci* 2005; 62:2150-2160.
34. Barter PJ, Rye K-A. The rationale for using apoA-I as a clinical marker of cardiovascular disease. *J Intern Med* 2006; 259:447-454.
35. Julve J, Escola-Gil JC, Rotllan N, Fievet C, Vallez E, de la Torre C, Ribas V, Sloan JH, Blanco-Vaca F. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. *Arterioscler Thromb Vasc Biol* 2010; 30:232-238.
36. Allayee H, Castellani LW, Cantor RM, de Bruin TWA, Lusis AJ. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. *Circ Res* 2003; 92:1262-1267.
37. Stan S, Delvin E, Lambert M, Seidman E, Levy E. Apo A-IV: an update on regulation and physiologic functions. *BiochimBiophysActa* 2003; 1631:177-187.
38. Steinmetz A, Utermann G. Activation of lecithin-cholesterol acyltransferase by human apolipoprotein A-IV. *J Biol Chem* 1985; 260:2258-2264.
39. Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects of purified apolipoprotein A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. *J Lipid Res* 1994; 35:982-992.
40. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL. Lipoprotein apoC-II activation of lipoprotein lipase - modulation by apolipoprotein A-IV. *J Biol Chem* 1990; 265:4266-4272.
41. Recalde D, Ostos MA, Badell E, Garcia-Otin A-L, Pidoux J, Castro G, Zakin MM, Scott-Algara D. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic

effects of a chronic infection mimicked by lipopolysaccharide. *Arterioscler Thromb Vasc Biol* 2004; 24:756-761.

42. Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, Lingenhel A, Kraft H-G, Weidinger F, Pachinger O, Dieplinger H, Kronenberg F. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. *J Lipid Res* 2003; 44:1523-1529.

43. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J. Apolipoprotein A-V accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. *J Biol Chem* 2005; 280:21553-21560.

44. Ribalta J, Figuera L, Fernandez-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J. Newly identified apolipoprotein A V gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. *Clin Chem* 2002; 48:1597-1600.

45. Pennacchio LA, Rubin EM. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. *Arterioscler Thromb Vasc Biol* 2003; 23:529-534.

46. Lo C-M, Nordskog BK, Nauli AM, Zheng S, vonLemden SB, Yang Q, Lee D, Swift LL, Davidson NO, Tso P. Why does the gut choose apolipoprotein B 48 but not B 100 for chylomicron formation? *Am J Physiol Gastrointest Liver Physiol* 2008; 294:G344-G352.

47. Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. *Orphanet J Rare Dis* 2008; 3:19.

48. Whitfield AJ, Barrett PHR, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the apoB gene. *Clin Chem* 2004; 50:1725-1732.

49. Jong MC, Hofker MK, Havekes LM. Role of apoCs in lipoprotein metabolism – functional differences between apoC1, apoC2, and apoC3. *Arterioscler Thromb Vasc Biol* 1999; 19:472-484.

50. Berbee JFP, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PCN. Severe hypertriglyceridemia in human apoC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. *J Lipid Res* 2005; 46:297-306.

51. Reina M, Brunzell JD, Deeb SS. Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes. *J Lipid Res* 1992; 33:1823-1832.

52. Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. *J Atheroscler Thromb* 2009; 16:6-11.

53. Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein CIII: understanding an emerging cardiovascular risk factor. *Clin Sci* 2008; 114:611-624.

54. Kotite L, Zhang L-H, Yu Z, Burlingame AL, Havel RJ. Human apoC-IV isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins. *J Lipid Res* 2003; 44:1387-1394.

55. Allan CM, Taylor JM. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice. *J Lipid Res* 1996; 37:1510-1518.

56. Perdomo G, Dong HH. Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging. *Aging* 2009; 1:17-27.

57. Kockx M, Jessup W, Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. *Arterioscler Thromb Vasc Biol* 2008; 28:1060-1067.

58. Raffe RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. *Arterioscler Thromb Vasc Biol* 2005; 25:436-441.

59. Mahley RW, Huang Y, Rall Jr SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. *J Lipid Res* 1999; 40:1933-1949.

60. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. *JAMA* 2007; 298:1300-1311.
61. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. *J Lipid Res* 2009; 50:S183-S188.
62. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. *J Lipid Res* 2002; 43:1997-2006.
63. Rufibach LE, Duncan SA, Battle M, Deeb SS. Transcriptional regulation of the human hepatic lipase (LIPC) gene promoter. *J Lipid Res* 2006; 47:1463-1477.
64. Yasuda T, Ishida T, Rader TJ. Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. *Circ J* 2010; 74:2263-2270.
65. Nagai Y, Aoki J, Sato T, Amano K, Matsuda Y, Arai H, Inoue K. An alternative splicing form of phosphatidylserine-specific phospholipase A1 that exhibits lysosphosphatidylserine-specific lysophospholipase activity in humans. *Cancer Res* 1995; 55:6237-6243.
66. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. *J Lipid Res* 2009; 50:S237-S242.
67. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. *Clin Microbiol Rev* 2000; 13:122-143.
68. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin:Cholesterol Acyltransferase: from biochemistry to role in cardiovascular disease. *Curr Opin Endocrinol Diabetes Obes* 2009; 16:163-171.
69. Masson D, Jiang X-C, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. *J Lipid Res* 2009; 50:S201-206.
70. Hussain MM, Bakillah A. New approaches to target microsomal triglyceride transfer protein. *Curr Opin Lipidol* 2008; 19:572-578.
71. Chang TY, Li BL, Chang CC, Urano Y. Acyl-coenzyme A:cholesterol acyltransferase. *Am J Physiol Endocrinol Metab* 2009; 297:E1-E9.
72. Brown TM, Bittner V. Biomarkers of atherosclerosis: clinical applications. *Curr Cardiol Rep* 2008; 10:497-504.
73. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. *J Atheroscler Thromb* 2010; 17:1-11.
74. Baldassarre D, De Jong A, Amato M, Werba JP, Castelnuovo S, Frigerio B, Veglia F, Tremoli E, Sirtori CR. Carotid intima-media thickness and markers of inflammation, endothelial damage and hemostasis. *Ann Med* 2008; 40:21-44.
75. Schlager O, Exner M, Mlekusch W, Sabeti S, Amighi J, Dick P, Wagner O, Koppensteiner R, Minar R, Schillinger M. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. *Stroke* 2007; 38:1263-1268.
76. Danesh J, Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. *JAMA* 2005; 294:1799-1809.
77. Sabeti S, Exner M, Mlekusch W, Amighi J, Quehenberger P, Rumpold H, Maurer G, Minar E, Wagner O, Schillinger M. Prognostic impact of fibrinogen in carotid atherosclerosis. Nonspecific indicator of inflammation or independent predictor of disease progression? *Stroke* 2005; 36:1400-1404.
78. Eldibany MM, Caprini JA. Hyperhomocysteinemia and Thrombosis. *Arch Pathol Lab Med* 2007; 131:872-884.
79. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. *Cell Death Differ* 2004; 11:S56-S64.

80. Ciaccio M, Bivona G, Bellia C. Therapeutical approach to plasma homocysteine and cardiovascular risk reduction. *Ther Clin Risk Manag* 2008; 4:219-224.
81. Chauffe RJ, Wilensky RL, Mohler III ER. Recent developments with lipoprotein-associated phospholipase A2 inhibitors. *Curr Atheroscler Rep* 2010; 12:43-47.
82. Tsimikas S, Tsimikas LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. *Arterioscler Thromb Vasc Biol* 2007; 27:2094-2099.
83. Garza CA, Montori VM, McConnell JP, Somers VR, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. *Mayo Clin Proc* 2007; 82:159-165.
84. Siekmeier R, Grammer TB, Scharnagl H, Stojakovic T, König W, März W. Lipoprotein-assoziierte Phospholipase A2: ein neuer Marker für kardiovaskuläre Erkrankungen. *J Lab Med* 2010; 34:217-222.
85. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. *Circulation* 2002; 105:1135-1143.
86. Napoli C, Lerman LO, de Nigris F, Gossel M, Balestrieri ML, Lerman A. Rethinking primary prevention of atherosclerosis-related diseases. *Circulation* 2006; 114:2517-2527.
87. Versari D, Daghini E, Viridis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. *Diabetes Care* 2009; 32:S314-S321.
88. Kastelein JJP, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. *Eur Heart J* 2008; 29:849-858.
89. Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range. Prospective data from the carotid atherosclerosis progression study (CAPS). *Stroke* 2006; 37:87-92.
90. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. *Circulation* 1965; 31:321-327.
91. Krebs K, März W. *Lipidsprechstunde: Praxisrelevante Fettstoffwechselstörungen und ihre Folgen*. Georg Thieme Verlag Stuttgart, New York, 2005.
92. Hegele RA, Ban MR, Hsueh N, Kennedy BA, Cao H, Zou GY, Anand S, Yusuf S, Huff MW, Wang J. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. *Hum Mol Genet* 2009; 18:4189-4194.
93. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *J Clin Invest* 2003; 111:1795-1803.
94. Pejic RN, Lee DT. Hypertriglyceridemia. *J Am Board Fam Med* 2006; 19:310-316.
95. Kiss RS, Kavaslar N, Okuhira K, Freeman MW, Walter S, Milne RW, McPherson R, Marcel YL. Genetic etiology of isolated low HDL syndrome. *Arterioscler Thromb Vasc Biol* 2007; 27:1139-1145.
96. Lichtenstein AH. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. *J Lipid Res* 2006; 47:1661-1667.
97. Orzano AJ, Scott JG. Diagnosis and treatment of obesity in adults: an applied evidence-based review. *J Am Board Fam Pract* 2004; 17:359-369.
98. Lin Y, Mousa SS, Elshourbagy N, Mousa SA. Current status and future direction in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets of therapy. *Vasc Health Risk Manag* 2010; 6:73-85.

99. Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. *Lipids Health Dis* 2010; 9:80-87.
100. Thompson GR. Management of dyslipidaemia. *Heart* 2004; 90:949-955.
101. Dihazi H, Koziolok MJ, Söllner T, Kahler E, Klingel R, Neuhoff R, Strutz F, Mueller GA. Protein adsorption during LDL-apheresis: proteomic analysis. *Nephrol Dial Transplant* 2008; 23:2925-2935.
102. Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buerni M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. *Kidney Blood Press Res* 2010; 33:100-110.
103. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, Kaaja R, Mikkola T, Palacios S, Preston R, Simon T, Stevenson J, Stramba-Badiale M. Management of cardiovascular risk in the perimenopausal woman: a consensus statement of European cardiologists and gynaecologists. *Eur Heart J* 2007; 28:2028-2040.
104. Kalantzi KI, Milionis HJ, Goudevenos IA. Management of the elderly patient with hyperlipidaemia: recent concerns. *Hellenic J Cardiol* 2006; 47:93-99.
105. Daniels SR, Greer FR, and the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. *Pediatrics* 2008; 122:198-208.